The provided text discusses the safety and tolerability profile of the compound CMS121, drawing information from preclinical animal studies and a completed Phase I clinical trial in healthy human subjects.
Animal studies indicated no significant adverse effects, even demonstrating benefits like increased lifespan in some models and good toleration in disease models without organ toxicity.
The Phase I trial further supported its safety, showing that oral administration of CMS121, even at high doses, was generally well-tolerated, with most side effects being mild and transient, primarily gastrointestinal issues or headaches. Importantly, no significant abnormalities were found in laboratory tests related to liver, kidney, or blood function, nor in cardiac parameters.
The text also notes favorable pharmacokinetics, including increased concentration in older individuals and improved bioavailability with food, ultimately concluding that CMS121 exhibits an encouraging safety profile at this stage of development.
Pure, targeted CMS-121 molecule designed to provide deep support for the brain, mitochondria, and cognitive resilience.
As the science of longevity and metabolic health evolves, few molecules have garnered as much attention as nicotinamide adenine dinucleotide (NAD⁺). Widely recognized as a coenzyme crucial for energy metabolism, DNA repair, and cell survival, NAD⁺ levels naturally...
As global life expectancy increases, so does the demand for strategies to maintain cognitive health. From aging populations to young professionals seeking mental clarity, brain performance is becoming the next frontier of functional nutrition
Nicotinamide mononucleotide (NMN) has gained global attention as a powerful NAD⁺ precursor with potential to combat aging and boost cellular health. But beyond longevity hype, what does the science really say—especially about its effects on the digestive system?
Can a molecule inspired by strawberries help fight one of the most complex diseases of our time? CMS-121, a refined derivative of fisetin, shows promising neuroprotective effects in preclinical models of Alzheimer’s.
